Dyskinesia (DBCOND0017935)

Identifiers

Synonyms

Dyskinetic event / Dyskinesias / Dyskinetic movements / Hyperkinetic Movement Disorders / Dystonia, unspecified / Dyskinetic syndrome / Syndrome dyskinetic / Dyskinesia (finding) / Dystonia / Oral Dyskinesia / Oral dyskinesia (disorder)

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Amantadine	A medication used to treat dyskinesia in Parkinson's patients receiving levodopa, as well as extrapyramidal side effects of medications.	D(2) dopamine receptortarget Matrix protein 2target Aromatic-L-amino-acid decarboxylaseenzyme Amine oxidase [flavin-containing] Benzyme Solute carrier family 22 member 2transporter Solute carrier family 22 member 1transporter Glutamate receptor ionotropic, NMDA 3Atarget Neuronal acetylcholine receptor subunit alpha-7target Neuronal acetylcholine receptor subunit alpha-4target Neuronal acetylcholine receptor subunit alpha-3target
Pipenzolate	An antimuscarinic agent indicated in the treatment of gastrointestinal motility disorders and arrhythmia.	No drug targets

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT00105521	Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia	Sarizotan	treatment	3	completed
NCT02202551	Open-Label Safety Study of ADS-5102 in PD Patients With LID	Amantadine	treatment	3	completed
NCT01937078	Famotidine for Levodopa-induced Dyskinesia in PD	Famotidine	treatment	2	completed
NCT01429207	Capturing Parkinson's Disease Medication Side Effects During Daily Activities	No drug interventions	Not Available	Not Available	completed
NCT05206513	Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy	Valbenazine	treatment	3	recruiting
NCT02439125	A Study of Efficacy and Safety of Eltoprazine HCl for Treating Levodopa-induced Dyskinesia in Parkinson's Disease Patients	Eltoprazine	treatment	2	unknown_status
NCT01767129	Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients	Dextromethorphan Quinidine	treatment	2	completed
NCT00105508	Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia	Sarizotan	treatment	3	completed
NCT00314288	Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia	Sarizotan	treatment	2	completed
NCT01397422	Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)	Amantadine	treatment	2 / 3	completed
NCT02274766	Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia	Amantadine	treatment	3	completed
NCT00114595	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia	Icosapent	treatment	4	completed
NCT02136914	ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)	Amantadine	treatment	3	completed
NCT05516875	Open-Label Extension Study of ASTORIA	No drug interventions	treatment	2	terminated
NCT06585605	A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes	No drug interventions	Not Available	Not Available	recruiting
NCT06618157	Connectomic Guided DBS for Parkinson's Disease	No drug interventions	treatment	Not Available	not_yet_recruiting
NCT05317390	Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia	No drug interventions	diagnostic	Not Available	recruiting
NCT01474421	Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease	No drug interventions	treatment	2	completed
NCT00467597	Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1)	Levodopa	Not Available	Not Available	completed
NCT01491932	Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias	Mavoglurant	treatment	2	completed
NCT05116813	Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy	Dipraglurant	treatment	2 / 3	unknown_status
NCT04553835	Effects of Rhythmic Auditory Stimulation on Movements in Individuals at Risk for Psychotic Onset and Schizophrenia Patients	No drug interventions	treatment	Not Available	unknown_status
NCT00888186	Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics	Carbidopa Levodopa	treatment	4	completed
NCT00004576	Study of LY300164 for the Treatment of Parkinson's Disease	Talampanel	treatment	2	completed
NCT04351360	Pilot Study on Caffeine Efficiency in ADCY5-related Dyskinesia	No drug interventions	Not Available	Not Available	unknown_status
NCT01491529	Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias	Mavoglurant	treatment	2	completed
NCT03270189	Effect of the Visual Information Change in Functional Dystonia	No drug interventions	treatment	Not Available	terminated
NCT01385592	Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias	Mavoglurant	treatment	2	completed
NCT05044572	Comparison of Open Chain Kinetic Exercises and Forward Head Posture Correction in Type II Scapular Dyskinesia	No drug interventions	treatment	Not Available	completed
NCT03956979	A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia	No drug interventions	treatment	2	completed
NCT04377945	Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components	No drug interventions	treatment	2	terminated
NCT04912115	Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia	Ketamine Midazolam	treatment	2	suspended
NCT04857359	Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy	Dipraglurant	treatment	2 / 3	unknown_status
NCT00036296	Effects of Talampanel on Patients With Advanced Parkinson's Disease	Talampanel	treatment	1 / 2	completed
NCT00076674	Levetiracetam Treatment of L-dopa Induced Dyskinesias	Levodopa	treatment	2	completed
NCT00363727	Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's	Ropinirole	treatment	3	completed
NCT04086160	Effects of Transcranial Direct Current Stimulation (tDCS) on Motor Function in Schizophrenia Patients and Individuals at Risk for Psychotic Onset	No drug interventions	treatment	Not Available	recruiting
NCT00086294	ACP-103 to Treat Parkinson's Disease	Levodopa Pimavanserin	treatment	2	completed
NCT02589340	Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia	Buspirone	treatment	1	terminated
NCT00360568	Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects	Carbidopa Levodopa	treatment	3	completed
NCT04929795	Effects of Music Beat on Motor Function in Individuals at Risk for Psychotic Onset and Schizophrenia Patients	No drug interventions	treatment	Not Available	recruiting
NCT04453995	A Follow-up of the Influencing Factors of Dyskinesia in Patients With Parkinson's Disease	No drug interventions	Not Available	Not Available	unknown_status
NCT00986414	Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease	Mavoglurant	treatment	2	completed
NCT03034538	An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease	Zonisamide	treatment	4	suspended
NCT00642057	Compassionate Use of Tetrabenazine in the Treatment of Abnormal Movements	Tetrabenazine	Not Available	Not Available	no_longer_available